(NASDAQ:ATRA) institutional sentiment improved to one.97 in Q2 2019. Its up 0.54, from 1.Forty three in 2019Q1. The ratio is higher, as seventy one hedge budget improved and commenced new fairness positions, even as 36 reduced and sold their positions in Atara Biotherapeutics. The hedge price range in our companion’s database now keep: 47.93 million stocks, up from forty six.79 million stocks in 2019Q1. Also, the wide variety of hedge price range protecting Atara Biotherapeutics of their pinnacle 10 fairness positions decreased from 3 to one for a decrease of two. Sold All: 19 Reduced: 17 Increased: 47 New Position: 24.
Atara Biotherapeutics, Inc., a scientific-level biopharmaceutical organization, specializes in developing treatments for patients with excessive and life-threatening sicknesses inside the United States. The organisation has marketplace cap of $849.36 million. The Company’s clinical level T-cell product candidates consist of ATA129 that makes a speciality of Phase III medical trials for the treatment of rituximab-refractory epstein-barr virus related post-transplant lymphoproliferative disorder after hematopoietic mobile transplant and strong organ transplant; ATA188, which is in Phase I medical trial for the remedy of multiple sclerosis; ATA520, a Phase I scientific trial product concentrated on cancers expressing the antigen Wilms tumor 1; and ATA230, that's Phase III clinical trials for refractory cytomegalovirus. It presently has bad profits. The company is likewise developing a next generation of allogeneic T-cellular product candidates utilizing a era to selectively beautify a T-cellÂ’s capacity to goal unique viral proteins implicated in ailment.
The stock multiplied 3.81% or $zero.58 over the last trading consultation, achieving $15.81. About 1.32M shares traded or fifty five.74% up from the common. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 60.20% when you consider that September 21, 2018 and is downtrending. It has underperformed by way of 60.20% the S&P500.
Analysts look ahead to Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to document earnings on November, five. They count on $-1.40 profits according to share, down 8.53 % or $zero.11 from remaining year’s $-1.29 per percentage. After $-1.60 real earnings according to percentage said with the aid of Atara Biotherapeutics, Inc. For the previous area, Wall Street now forecasts -12.50 % EPS growth.
Bridger Management Llc holds 2.Seventy one% of its portfolio in Atara Biotherapeutics, Inc. For 1.Seventy two million stocks. Redmile Group Llc owns four.60 million shares or 2.Sixty two% in their US portfolio. Moreover, Baupost Group Llc Ma has 1.27% invested inside the business enterprise for 7.00 million stocks. The Luxembourg-based totally Artal Group S.A. Has invested 0.94% inside the stock. Trellus Management Company Llc, a New York-based fund pronounced 25,000 stocks.
Since January 1, 0001, it had 1 buying transaction, and zero insider sales for $39,000 interest.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Coverage
Ratings evaluation reveals 50% of Atara Biotherapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Atara Biotherapeutics, 1 provide it “Buy”, 0 “Sell” score, even as 1 suggest “Hold”. The lowest goal is $1500 even as the high is $70. The inventory’s average target of $42.50 is 168.82% above today’s ($15.81) proportion fee. ATRA became blanketed in five notes of analysts from March 22, 2019. The rating turned into maintained by way of Canaccord Genuity with “Buy” on Friday, March 22. Jefferies downgraded Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, September sixteen to “Hold” score.
More first rate latest Atara Biotherapeutics, Inc. (NASDAQ:ATRA) information have been published by using: Seekingalpha.Com which launched: “Atara: Shifting Toward CAR-T – Seeking Alpha” on July 05, 2019, additionally Globenewswire.Com with their article: “Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences – GlobeNewswire” published on May 30, 2019, Benzinga.Com published: “The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, three Biotechs To IPO – Benzinga” on June 27, 2019. More exciting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) had been launched through: Globenewswire.Com and their article: “Atara Biotherapeutics to Participate in Upcoming Conferences – GlobeNewswire” published on March 07, 2019 in addition to Nasdaq.Com‘s news article titled: “Are Options Traders Betting on a Big Move in Atara (ATRA) Stock? – Nasdaq” with publication date: August 28, 2019.
Atara Biotherapeutics, Inc., a scientific-level biopharmaceutical organization, specializes in developing treatments for patients with excessive and life-threatening sicknesses inside the United States. The organisation has marketplace cap of $849.36 million. The Company’s clinical level T-cell product candidates consist of ATA129 that makes a speciality of Phase III medical trials for the treatment of rituximab-refractory epstein-barr virus related post-transplant lymphoproliferative disorder after hematopoietic mobile transplant and strong organ transplant; ATA188, which is in Phase I medical trial for the remedy of multiple sclerosis; ATA520, a Phase I scientific trial product concentrated on cancers expressing the antigen Wilms tumor 1; and ATA230, that's Phase III clinical trials for refractory cytomegalovirus. It presently has bad profits. The company is likewise developing a next generation of allogeneic T-cellular product candidates utilizing a era to selectively beautify a T-cellÂ’s capacity to goal unique viral proteins implicated in ailment.
The stock multiplied 3.81% or $zero.58 over the last trading consultation, achieving $15.81. About 1.32M shares traded or fifty five.74% up from the common. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 60.20% when you consider that September 21, 2018 and is downtrending. It has underperformed by way of 60.20% the S&P500.
Analysts look ahead to Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to document earnings on November, five. They count on $-1.40 profits according to share, down 8.53 % or $zero.11 from remaining year’s $-1.29 per percentage. After $-1.60 real earnings according to percentage said with the aid of Atara Biotherapeutics, Inc. For the previous area, Wall Street now forecasts -12.50 % EPS growth.
Bridger Management Llc holds 2.Seventy one% of its portfolio in Atara Biotherapeutics, Inc. For 1.Seventy two million stocks. Redmile Group Llc owns four.60 million shares or 2.Sixty two% in their US portfolio. Moreover, Baupost Group Llc Ma has 1.27% invested inside the business enterprise for 7.00 million stocks. The Luxembourg-based totally Artal Group S.A. Has invested 0.94% inside the stock. Trellus Management Company Llc, a New York-based fund pronounced 25,000 stocks.
Since January 1, 0001, it had 1 buying transaction, and zero insider sales for $39,000 interest.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Coverage
Ratings evaluation reveals 50% of Atara Biotherapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Atara Biotherapeutics, 1 provide it “Buy”, 0 “Sell” score, even as 1 suggest “Hold”. The lowest goal is $1500 even as the high is $70. The inventory’s average target of $42.50 is 168.82% above today’s ($15.81) proportion fee. ATRA became blanketed in five notes of analysts from March 22, 2019. The rating turned into maintained by way of Canaccord Genuity with “Buy” on Friday, March 22. Jefferies downgraded Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, September sixteen to “Hold” score.
More first rate latest Atara Biotherapeutics, Inc. (NASDAQ:ATRA) information have been published by using: Seekingalpha.Com which launched: “Atara: Shifting Toward CAR-T – Seeking Alpha” on July 05, 2019, additionally Globenewswire.Com with their article: “Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences – GlobeNewswire” published on May 30, 2019, Benzinga.Com published: “The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, three Biotechs To IPO – Benzinga” on June 27, 2019. More exciting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) had been launched through: Globenewswire.Com and their article: “Atara Biotherapeutics to Participate in Upcoming Conferences – GlobeNewswire” published on March 07, 2019 in addition to Nasdaq.Com‘s news article titled: “Are Options Traders Betting on a Big Move in Atara (ATRA) Stock? – Nasdaq” with publication date: August 28, 2019.